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PPEDIATRIC CARDIOLOGY
Recipient Genotype Is a Predictor
of Allograft Cytokine Expression and
Outcomes After Pediatric Cardiac Transplantation
Scott R. Auerbach, MD,* Cedric Manlhiot, BS,§ Sushma Reddy, MD,* Caroline Kinnear, MS,*
Marc E. Richmond, MD,* Dorota Gruber, MS,* Brian W. McCrindle, MD, MPH,§
Liyong Deng, MS,‡ Jonathan M. Chen, MD,† Linda J. Addonizio, MD,* Wendy K. Chung, MD,‡
Seema Mital, MD§
New York, New York; and Toronto, Ontario, Canada
Objectives This study sought to investigate the influence of recipient renin-angiotensin-aldosterone system (RAAS) genotype
on cardiac function, rejection, and outcomes after heart transplantation.
Background The RAAS influences cardiac function and up-regulates inflammatory/immune pathways. Little is known about
the effect of recipient RAAS polymorphisms in pediatric cardiac transplantation.
Methods Patients 25 years of age, after cardiac transplantation, were enrolled (2003 to 2008) and genotyped for poly-
morphisms in genes associated with RAAS upregulation: AGT-G, ACE-D, AGTR1-C, CYP11B2-G, and CMA-A. Pres-
ence of at least 1 high-risk allele was defined as a high-risk genotype. Univariable and multivariable associations
between genotypes and outcomes were assessed in time-dependent models using survival, logistic, or linear
regression models. Biopsy samples were immunostained for interleukin (IL)-6, transforming growth factor
(TGF)-, and tumor necrosis factor (TNF)- during rejection and quiescence.
Results A total of 145 patients were studied, 103 primary cohort and 42 replication cohort; 81% had rejection, 51% had
graft dysfunction, and 13% had vasculopathy, 7% died and 8% underwent re-transplantation. A higher number of
homozygous high-risk RAAS genotypes was associated with a higher risk of graft dysfunction (hazard ratio [HR]:
1.5, p  0.02) and a higher probability of death (HR: 2.5, p  0.04). The number of heterozygous high-risk RAAS
genotypes was associated with frequency of rejection (0.096 events/year, p  0.001) and rejection-associated
graft dysfunction (0.37 events/year, p  0.002). IL-6 and TGF- were markedly upregulated during rejection in
patients with 2 high-risk RAAS genotypes.
Conclusions Recipient RAAS polymorphisms are associated with a higher risk of rejection, graft cytokine expression, graft
dysfunction, and a higher mortality after cardiac transplantation. This may have implications for use of RAAS
inhibitors in high-risk patients after transplantation. (J Am Coll Cardiol 2009;53:1909–17) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.027a
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an recent years, survival after pediatric heart transplantation
as improved to 90% at 1 year and 70% at 5 years (1).
espite improved survival and quality of life, post-
ransplantation cardiac function is not normal. Almost 30%
f patients show evidence of cardiac dysfunction by 10 years
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merican Academy of Pediatrics National Conference and Exhibition, October 26,
007, and American Heart Association Annual Meeting, November 5, 2007.i
Manuscript received November 17, 2008; revised manuscript received February 13,
009, accepted February 19, 2009.fter transplantation (2), accounting for up to 20% of deaths
n children after transplantation and causing significant
orbidity in survivors (1).
The causes of graft dysfunction are many and include
ystemic hypertension, allograft rejection, and graft vascu-
opathy. The latter two are the leading causes of mortality
1,3). Neurohormonal systems may play an important role
n the pathogenesis of graft dysfunction. A major such
ystem regulating cardiac function and hemodynamics is the
enin-angiotensin-aldosterone system (RAAS). Activation
f the RAAS causes peripheral vasoconstriction and also
cts at the cellular level to cause cardiomyocyte hypertrophy,
poptosis, and fibrosis (4–6). In addition, RAAS activation
s associated with up-regulation of cytokines and inflamma-
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RAAS Genotypes in Pediatric Heart Transplantation May 19, 2009:1909–17tory pathways that may increase
the risk of rejection and exacer-
bate immune-mediated myocar-
dial injury (7–10). The different
steps in the RAAS signaling
pathways are regulated by indi-
vidual genes, which are polymor-
phic. Polymorphisms that cause
up-regulation of the RAAS have
been associated with cardiac dys-
function and heart failure in pre-
vious studies in both children
and adults (6,11,12). In addition,
some polymorphisms in the
RAAS pathway genes have been
associated with a higher inci-
dence of graft vasculopathy in
the adult cardiac transplantation
population (13,14). Whether this
is related to increased cytokine
expression in the graft is not
known. The effect of RAAS
olymorphisms on cardiac allograft function, cytokine ex-
ression, and outcomes in children has not been previously
tudied. Also, although most studies have evaluated the
ffect of polymorphisms in individual RAAS genes, few
ave evaluated the effect of multiple RAAS polymorphisms
n the same patient (6,15). The purpose of this study was to
etermine the influence of recipient RAAS genotype on
ejection, graft cytokine expression, graft dysfunction, graft
asculopathy, and survival in children after cardiac
ransplantation.
ethods
his was a cohort study of patients 25 years of age with a
istory of cardiac transplantation who were followed up in
he pediatric cardiac transplantation clinic at 2 institutions:
organ Stanley Children’s Hospital of New York Presby-
erian between 2003 and 2006 (primary cohort, n  103)
nd Hospital for Sick Children, Toronto, between 2007 and
008 (replication cohort, n  42). The study protocol was
pproved by the Institutional Review Board of Columbia
niversity Medical Center and the Hospital for Sick Chil-
ren. Written informed consent was obtained from all
ubjects before enrollment.
linical data. Clinical data were obtained from a review of
he medical records. All patients underwent serial echocar-
iography and cardiac catheterization with endomyocardial
iopsy every 3 to 6 months as part of surveillance monitor-
ng for rejection, as well as annual coronary angiograms to
ssess graft vasculopathy. Data on the age at listing; sex;
ace/ethnicity; pre-transplantation diagnosis; date of trans-
lantation; need for pre- or post-transplantation mechanical
irculatory support, including extracorporeal membrane
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AGT  angiotensinogen
M235T
AGTR1  angiotensin II
type 1 receptor
CI  confidence interval
CMA  cardiac chymase A
CYP11B2  aldosterone
synthase
HR  hazard ratio
IL  interleukin
RAAS  renin-angiotensin-
aldosterone system
TGF  transforming growth
factor
TNF  tumor necrosis
factorxygenation or ventricular assist device; date of death; the pumber of episodes of rejection; use of angiotensin-
onverting enzyme inhibitors or -blockers; and echocar-
iographic variables were obtained from the medical
ecords. Hemodynamic data obtained at the time of cardiac
atheterization included central venous pressure, pulmonary
rtery pressure, pulmonary capillary wedge pressure, cardiac
ndex, and indexed systemic vascular resistance. Rejection
as defined as International Society of Heart Lung Trans-
lantation grade 1B or greater (advanced 1R or higher per
ew classification) (16) or clinical rejection. Graft dysfunc-
ion was defined as a shortening fraction 28%, pulmonary
apillary wedge pressure of 12 mm Hg, or a cardiac index
f 2.5 l/min/m2. Studies have shown that a pulmonary
apillary wedge pressure of 12 mm Hg can be prognostic
or both rejection and graft vasculopathy (17,18). Graft
asculopathy was defined as pruning or stenosis on coronary
ngiography and was based on the Stanford classification
ystem (19).
enotyping RAAS. A blood or saliva sample was obtained
or deoxyribonucleic acid extraction. Patients were geno-
yped for polymorphisms in genes associated with RAAS
p-regulation. The following polymorphisms were evalu-
ted: 1) a M235T missense variant in angiotensinogen
AGT); 2) a deletion variant of angiotensin-converting
nzyme (ACE), in intron 16; 3) an A/G polymorphism at
ucleotide 1,903 of the cardiac chymase a gene (CMA); 4)
n A/C polymorphism at nucleotide 1,666 of angiotensin II
ype 1 receptor (AGTR1); and 5) a C/T polymorphism at
ucleotide 344 in aldosterone synthase (CYP11B2) (20).
he clinicians caring for the patients were unaware of the
atients’ genotypes. Candidate gene polymorphisms in the
AAS neurohormonal axis were selected based on previous
ssociation studies, known functional effects of the poly-
orphisms, and allele frequency in the population
4,11,15). The RAAS genotypes were determined in all
ubjects by pyrosequencing assays for AGTR1, CYP11B2,
GT, and CMA and electrophoresis of polymerase chain
eaction products for the ACE assay as previously described
6). Primer sequences are shown in Table 1.
mmunostaining of endomyocardial biopsy samples for
ytokine expression. Paired biopsy samples obtained from
subset of 31 patients during episodes of rejection and
uiescence were immunostained for cytokine expression.
araffin-embedded sections of myocardium were immuno-
tained using a rabbit polyclonal to interleukin (IL)-6
1:400), a mouse monoclonal to transforming growth factor
TGF)- (1:30), and a rabbit polyclonal to tumor necrosis
actor (TNF)- (1:150) (all from Abcam, Cambridge,
assachusetts) as primary antibodies. A horseradish perox-
dase conjugated streptavidin and diamino benzidine
ethod (Histostain kit, Zymed Laboratories, Invitrogen,
arlsbad, California) was used according to the manufac-
urer’s protocol. IL-6, TGF-, and TNF- staining were
isualized in tissue sections at 200 magnification. For the
urpose of this comparison, high-risk was defined as the
resence of 2 homozygous high-risk RAAS genotypes (1
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May 19, 2009:1909–17 RAAS Genotypes in Pediatric Heart Transplantationf which was AGT), and low-risk as 2 homozygous
igh-risk RAAS genotypes. The distribution and intensity
f staining was compared qualitatively between the high-
nd low-risk groups.
tatistical analysis. Data are presented as means with
tandard deviation, medians with minimum and maximum,
nd frequencies as appropriate. Time-dependent clinical
utcomes (death, graft vasculopathy, and graft dysfunction)
ere modeled with Kaplan-Meier, nonparametric survival
odels, whereas rejection episodes with or without graft
ysfunction were expressed as number of events per patient-
ear. Effect of the high-risk allele was evaluated in both the
eterozygous and homozygous forms (additive model).
nivariable associations between individual gene polymor-
hisms and frequency of rejection and frequency of rejection
ith graft dysfunction were assessed in linear regression
odels, whereas associations with freedom from cardiac
ysfunction, graft vasculopathy, retransplantation, and
eath were assessed in survival models. Individual gene
olymorphisms found to be significantly associated with
utcomes in univariable models were then included in
ultivariable analyses to obtain a final model for each
utcome. Parameter estimates of associations between out-
omes and individual RAAS genes (from the univariable
nalysis) were converted from the original regression models
o odds ratio or hazard ratio (HR) as appropriate to allow
or meaningful comparison across outcomes. Exponential
athematical transformations were performed on frequency
f rejection and frequency of rejection associated with graft
ysfunction to account for the skewed distribution of those
rimer Sequences for the Renin-ngiotensin-Aldo terone System Genotype Assays
Table 1 Primer Sequences for the Renin-Angiotensin-Aldosterone System Genotype Assays
Angiotensinogen
AGT-F GGTGGTCACCAGGTATGTCC
AGT-R AGGCTGTGACAGGATGGAAG
AGT-seq-F TGCTGTCCACACTGGCTCCC
Angiotensin-converting enzyme
ACE3as GCCCTGCAGGTGTCTGCAGCATGT
ACE3as GGATGGCTCTCCCCGCCTTGTCTC
ACE5a TGGGACCACAGCGCCCGCCACTAC
ACE5c TCGCCAGCCCTCCCATGCCCATAA
Chymase
CMA-F TTCCATTTCCTCACCCTCAG
CMA-R CAGAAGAGAATCCGGAGCTG
CMA-seq-F CACCCTCAGCCAGGCAGGTG
Aldosterone synthase
CYP11B2-F TGGAGGGTGTACCTGTGTCA
CYP11B2-R TCCAGGGCTGAGAGGAGTAA
CYP11B2-seq-R CTTATCGTGAGATGAGAGGG
Angiotensin II receptor, type I
AGTR1-F AGAAGCCTGCACCATGTTTT
AGTR1-R TGTGGCTTTGCTTTGTCTTG
AGT1-seq-F CACTTCACTACCAAATGAGC
rom the National Center for Biotechnology Information dbSNP public database. Available at:
ttp://www.ncbi.nlm.nih.gov/SNP/.utcomes (Shapiro-Wilk test for transformed data p  0.05
A
fin both cases). To facilitate interpretation of exponentially
ransformed data, reverse-transformation was used to obtain
ean differences and 95% confidence intervals (CIs). A
eplication cohort of 42 patients from the Hospital for Sick
hildren enrolled from 2007 to 2008 underwent RAAS
enotyping to assess the effect of the RAAS genotype on
raft function. All statistical analyses were performed using
AS Statistical Software version.9.1 (SAS Institute Inc.,
ary, North Carolina).
esults
rimary cohort. Of 222 patients who underwent trans-
lantation, 103 survivors of transplantation who were
ounger than 25 years of age and followed up at our
nstitution were enrolled in the study as the primary cohort.
ear of transplantation ranged from 1989 to 2006, with a
ean follow-up of 5.7  3.8 years. Enrollment occurred at
ariable times after transplantation. Maintenance immuno-
uppression consisted of a combination 2 to 6 mg/kg/day
yclosporine that was titrated to maintain appropriate serum
yclosporine levels. Patients were switched from cyclospor-
ne to tacrolimus (0.05 to 0.1 mg/kg/day) if rejection was
oted in the setting of therapeutic cyclosporine levels.
ntiproliferative agents included azathioprine (1 to 2 mg/
g/day) or mycophenolate mofetil (25 to 50 mg/kg/day).
rednisone was initiated at 1 to 2 mg/kg/day and then
apered. Prednisone was discontinued by 1 year post-
ransplantation if rejection free. Induction therapy was not
outinely used at our institution during the study period.
emographics and patient characteristics are listed in Table 2,
nd echocardiographic and hemodynamic data at last
ollow-up are listed in Table 3. During the follow-up
eriod, 81% of patients had rejection (34 had grade 1B, 2,
r 2R rejection, 37 had grade 3A or 3R rejection, and 14
ad clinical rejection). Graft dysfunction developed in 51
atient Characteristics (n  103)
Table 2 Patient Characteristics (n  103)
Female 60 (58%)
Ethnicity
African American 19 (18%)
White 51 (50%)
Hispanic 18 (17%)
Asian 7 (7%)
Other 8 (8%)
Diagnosis
Cardiomyopathy 71 (69%)
Congenital heart disease 32 (31%)
Mean age at transplantation (yrs) 8.4 6.8
Mean age at last follow-up (yrs) 14.7 6.7
Mean time to last follow-up (yrs) 5.7 3.8
Mean pre-transplantation GFR (ml/min/1.73 m2) 117 41 (32–198)
Mechanical circulatory support (pre-transplantation) 13/103 (12.6%)
ACE inhibitor or ARB pre-transplantation 57/88 (65%)
ACE or ARB use at last follow-up 22%CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; GFR  glomerular
ltration rate.
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RAAS Genotypes in Pediatric Heart Transplantation May 19, 2009:1909–17atients (51%), graft vasculopathy developed in 11 (12%),
eath occurred in 7 (7%), and retransplantation was per-
ormed in 8 (8%). Frequency of rejection episodes per year
as 1.05  0.93. Frequency of rejection episodes with graft
ysfunction was 0.44  0.61 per year.
At 5 years post-transplantation, 24% patients were receiving
ngiotensin-converting enzyme inhibitors or angiotensin re-
eptor blockers and 5% were receiving -blockers. There was
o difference in angiotensin-converting enzyme inhibitor or
-blocker use across genotypes. Kaplan-Meier survival curves
or graft dysfunction, graft vasculopathy, and survival for
he entire cohort are shown in Figures 1A, 1B, and 1C,
espectively.
requency of RAAS polymorphisms. The high-risk allele
requency was: ACE 51%, AGTR1 23%, AGT 59%,
YP11B2 35%, and CMA 42%. All genotypes were in
ardy-Weinberg equilibrium; the distribution of genotypes
s shown in Table 4. There was no difference in genotype
requencies based on race, sex, or diagnosis. The frequency
f at least 1 homozygous high-risk RAAS allele was 73%,
ith a median of 1 homozygous high-risk gene present.
umulative effect of multiple high-risk RAAS genotypes
n outcomes. Initial analysis assessed the cumulative effect
f multiple high-risk RAAS genes on outcomes. Freedom
rom graft dysfunction was 75% at 1 year and 57% at 5 years.
he presence of left ventricular hypertrophy and severity of
eft ventricular hypertrophy at 1 month after transplantation
as not associated with graft dysfunction (parameter esti-
ate: 0.137, SE: 0.450, p  0.76, HR: 0.87, 95% CI:
.36 to 2.11, and parameter estimate: 0.057, SE: 0.128,
 0.66, HR: 0.94, 95% CI: 0.73 to 1.21, respectively).
reedom from graft dysfunction for patients with no high-
isk RAAS genotype versus patients with at least 1 high-risk
AAS genotype is shown in Figure 2A. A higher number of
igh-risk RAAS genotypes was significantly associated with
higher risk of graft dysfunction (HR: 1.50, 95% CI: 1.08
o 2.07, p  0.02) (Fig. 2B), higher frequency of rejection
0.10 episodes/year, 95% CI: 0.05 to 0.15, p  0.001)
Fig. 3A), higher frequency of rejection episodes with graft
ysfunction (0.37 episodes/year, 95% CI: 0.12 to 0.70.
chocardiographic and Hemodynamic Data
Table 3 Echocardiographic and Hemodynamic Data
Data Mean  SD (Range)
Echocardiographic (last follow-up)
LV end-diastolic diameter, Z-score 0.9 1.3 (3.5 to 1.9)
Interventricular septum, Z-score 0.6 1.4 (2.9 to 4.4)
LV posterior wall diameter, Z-score 0.1 1.3 (3.0 to 3.2)
Shortening fraction, % 37 7 (13 to 51)
Hemodynamic (last follow-up)
Cardiac index by thermodilution, l/min/m2 3.4 1.0 (1.7 to 7.8)
Mean right atrial pressure, mm Hg 6 4 (1 to 25)
Mean pulmonary artery pressure, mm Hg 18 6 (8 to 39)
Mean pulmonary capillary wedge pressure,
mm Hg
11 5 (1 to 36)
V  left ventricular. 0.002) (Fig. 3B), and higher risk of death (HR: 2.53,5% CI: 1.08 to 5.94. p  0.04). The RAAS genotype did
ot influence the severity of rejection. However, subjects
ith the high-risk genotypes were more likely to have a
raft dysfunction develop during an episode of rejection,
ndependent of the severity of rejection. There was no
ssociation between the number of high-risk RAAS geno-
ypes and grade of rejection, graft vasculopathy, or retrans-
lantation. Although the association with frequency of
Figure 1 Kaplan-Meier Curves for the Entire Cohort
(A) Graft dysfunction, (B) graft vasculopathy, (C) survival.
Dashed lines represent 95% confidence interval for the Kaplan-Meier estimate.
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May 19, 2009:1909–17 RAAS Genotypes in Pediatric Heart Transplantationejection episodes was observed even in the presence of a
ingle high-risk allele, that is, heterozygous high-risk geno-
ypes, the association with graft dysfunction and survival
as seen only with the homozygous high-risk genotypes,
uggesting a gene-dosing effect.
ffect of individual high-risk RAAS genotypes on out-
omes. Associations between individual RAAS genotypes
nd clinical outcomes are shown in Figure 4. On univariable
nalysis, polymorphisms in individual RAAS genes were
ssociated with several adverse outcomes, including rejec-
ion, graft dysfunction, and death. On multivariable analy-
is, AGT was most consistently associated with adverse
utcomes, including a higher risk of graft dysfunction,
ejection, and rejection with graft dysfunction. In addition,
GT was associated with a markedly higher risk of graft
asculopathy, with an HR of 4.7 (95% CI: 1.12 to 9.61, p
.04). Of the other genotypes, there was an association
etween CMA and rejection with graft dysfunction in both
nivariable and multivariable analyses.
raft cytokine expression. Patients with 2 high-risk
AAS genotypes, all of whom were also homozygous for
he AGT polymorphism (n  16), showed significant
p-regulation of IL-6 and TGF- during rejection episodes
ompared with patients with 2 high-risk genotypes (n 
5) (Figs. 5A and 5B). Expression of TNF- did not
hange significantly during rejection in any group (Fig. 5C).
eplication cohort. The characteristics of the replication
ohort are shown in Table 5. The allele frequencies were in
ardy-Weinberg equilibrium. The high-risk gene frequen-
ies were as follows: ACE 62%, AGT 41%, AGTR 23%,
YP11B2 67%, and CMA 43%. Like the primary cohort, a
igher number of high-risk RAAS genes was associated
ith a greater likelihood of graft dysfunction (HR: 1.3, 95%
I: 1.0 to 1.8, p  0.05). This association was strongest
ith the AGTR genotype (HR: 2.3, 95% CI: 1.1 to 4.8, p
.03). The AGT high-risk genotype was associated with a
igher risk of graft dysfunction, but this did not reach
tatistical significance (HR: 1.6, 95% CI: 0.9 to 2.6, p 0.09).
iscussion
lthough outcomes after cardiac transplantation con-
inue to improve, there remains a high rate of graft
ailure, dysfunction, and retransplantation. With over
requency of High-Risk Alleles (n  103)
Table 4 Frequency of High-Risk Alleles (n  103)
1 High-Risk Allele 2 High-Risk Alleles
ACE 46 (45.6%) 29 (28.7%)
AGT 39 (39%) 39 (39%)
AGTR 27 (26.7%) 10 (9.9%)
CYP11B2 47 (46.5%) 12 (17.9%)
CHYM 49 (48.5%) 18 (17.8%)
CE  angiotensin converting enzyme gene polymorphism; AGT  angiotensinogen M235T gene
olymorphism; AGTR1  angiotensin II type 1 receptor gene polymorphism; CHYM  chymase;
YP11B2  aldosterone synthase gene polymorphism.,000 children receiving transplants in the past 10 years1), there is a significant health burden associated with
raft dysfunction and need for retransplantation in the
ontext of limited donor availability. As we begin to
nderstand how genetics plays a role in heart disease, it is
ecoming clear that risk stratification based on genotyp-
ng is possible and potentially beneficial. This is the first
tudy to identify recipient genetic predictors of graft
unction and survival after pediatric cardiac transplanta-
ion as well as to provide a potential mechanism for
enetic risk. A larger number of RAAS high-risk poly-
orphisms was associated with a higher incidence of
raft dysfunction, rejection, and rejection associated with
raft dysfunction, as well as lower survival. Polymor-
hisms in the AGT group were most highly associated
ith adverse outcomes after cardiac transplantation. The
ssociation of both heterozygous and homozygous carri-
rs of the high-risk genotypes with adverse outcomes
uggests a multiplicative effect of high-risk alleles. The
bservation of a cumulative effect of multiple RAAS
enes highlights the importance of studying genes that do
Figure 2 Effect of RAAS Genotype on Graft Dysfunction
(A) Freedom from graft dysfunction was lower in patients with 1 high-risk
renin-angiotensin-aldosterone system (RAAS) gene. This effect was seen only
with the homozygous high-risk RAAS genotypes. (B) The hazard of graft dys-
function increased by 1.5 (95% confidence interval: 1.08 to 2.07, p  0.02)
for each additional high-risk RAAS gene.
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RAAS Genotypes in Pediatric Heart Transplantation May 19, 2009:1909–17ot just regulate a single step, but that act additively or
ynergistically by influencing several steps in a biologic
athway. This is also the first study to show up-
Figure 3 Effect of RAAS Genotype on Rejection Frequency
(A) Annual frequency of rejection episodes per year and (B) rejection episodes wit
by 0.10 episodes/year (95% confidence interval: 0.05 to 0.15, p  0.001) for e
rejection episodes with graft dysfunction increased by 0.37 episodes/year (95%
The RAAS genotype was significantly associated with both rejection and rejection w
Figure 4 Effect of Individual RAAS Genotypes on Clinical Outco
The renin-angiotensin-aldosterone system (RAAS) genotype was significantly assoc
homozygous form. The RAAS genotype was associated with risk for rejection and f
mates in black represent significant associations in univariable models only; estim
number of high-risk RAAS genes was modeled alone. Log scales (power 2) were usegulation of cytokine expression in the grafts of patients
ith a high-risk RAAS genotype, providing a mechanis-
ic link between the RAAS and the immune system.
omitant graft dysfunction per year, by genotype. The risk of rejection increased
gh-risk renin-angiotensin-aldosterone system (RAAS) gene. The risk of having
ence interval: 0.12 to 0.70, p  0.002) for each additional high-risk RAAS gene.
aft dysfunction even in the heterozygous form.
ith the risk for death, graft loss, graft dysfunction, and graft vasculopathy in the
odes of rejection with graft dysfunction even in the heterozygous form. Esti-
in red represent statistically significant associations in multivariable models. The
r the horizontal axes; AGT was most consistently associated with adverse out-h conc
ach hi
confid
ith grmes
iated w
or epis
ates
ed fo
comes. CI  confidence interval.
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May 19, 2009:1909–17 RAAS Genotypes in Pediatric Heart TransplantationAlthough the adverse effects of chronic RAAS activation
n myocyte hypertrophy, apoptosis, and fibrosis are well
nown, this is the first study to report an association
etween the RAAS genotype and an increased susceptibility
o rejection and graft vasculopathy in the donor heart after
ardiac transplantation. This association between high-risk
AAS genotypes and a higher incidence of graft dysfunc-
ion occurred both during rejection and in the absence of
ejection, and was likely related to cytokine up-regulation.
revious studies have reported an association between
AAS activation and induction of inflammatory cytokines,
ost notably TGF-, IL-6, and TNF- in other condi-
ions. Upregulation of TGF- in response to increased
ngiotensin II increases cardiac fibrosis, extracellular matrix
eposition, and myocyte hypertrophy (8–10). Other studies
ave reported that increased IL-6 and TNF- expression is
ssociated with an increased incidence of allograft rejection
nd graft vasculopathy (8,21,22). The up-regulation of IL-6
nd TGF- during rejection in patients with a higher
umber of high-risk RAAS genotypes, in particular AGT,
rovides evidence of a link between the immune system and
he RAAS; AGT was most consistently associated with
dverse outcomes, and the increased levels of IL-6 and
GF- activity in these patients may be responsible for
oth rejection and immune-mediated myocardial injury,
esulting in graft dysfunction and graft vasculopathy. This
ssociation supports the idea that increased susceptibility of
he transplanted heart to graft dysfunction during rejection
n patients with the high-risk RAAS genotypes may be
elated to increased expression of these cytokines and
dverse cardiac morphometric changes. Increased expression
f cytokines may lead to a greater degree of myocyte damage
ndependent of the severity of cellular infiltration of the
yocardium. Cytokine up-regulation in biopsy samples may
rovide a new tissue biomarker for identifying patients at
isk for graft dysfunction as well as patients likely to benefit
rom cytokine inhibition. The possibility of a haplotype
eplication Cohort Characteristics (n  42)
Table 5 Replication Cohort Characteristics (n  42)
Male 24 (57%)
Etiology (congenital heart disease) 19 (45%)
Alive at last follow-up 42 (100%)
Graft loss 2 (5%)
Graft vasculopathy at last follow-up 4 (10%)
Graft dysfunction 14 (33%)
Freedom from graft dysfunction
3 months 74%
1 yr 72%
3 yrs 72%
5 yrs 67%
Episodes of rejection
None 13 (31%)
1 15 (36%)
2 14 (33%)
Rejection with graft dysfunction 1 (2%)Median duration of follow-up (yrs) 2.7 (0.18–12.06)Figure 5 Effect of RAAS Genotype
on Graft Cytokine Expression
Immunostaining with monoclonal antibodies against interleukin (IL)-6 (A), trans-
forming growth factor (TGF)- (B), and tumor necrosis factor (TNF)- (C) in
biopsy specimens during both high grade (i.e., 3A) rejection and quiescence
in high- and low-risk patients. Representative images from patients with high-
(#28) and low-risk (#5) genotypes show markedly increased expression of IL-6
and TGF- during rejection in patients with the high-risk genotypes only. There
was no increase in expression of TNF- during rejection in either low- (#26) or
high-risk (#3) genotype groups. All are 200 magnification. RAAS  renin-an-
giotensin-aldosterone system.
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ther immune-response-encoding genes requires further
nvestigation.
Although AGT polymorphisms have been shown to be
ssociated with elevated levels of circulating angiotensino-
en, cardiac hypertrophy, and a higher prevalence of heart
ailure, hypertension, and atherosclerosis (23–26), there are
imited data on the association of RAAS genotypes with
ost-transplantation outcomes. The ACE and AGTR1
igh-risk genotypes have previously been associated with
raft vasculopathy, but we know of no other reports of
ssociation of AGT with graft vasculopathy (13,14,27).
lthough overall results of studies of AGT in other solid
rgan transplants have been conflicting, 2 studies have
hown associations between the AGT and both chronic
llograft nephropathy and a shorter time to renal graft loss
28,29). Chronic allograft nephropathy is histologically
haracterized by vasculopathy, glomerulopathy, tubular at-
ophy, and interstitial fibrosis, with vascular lesions showing
mooth muscle cell proliferation and intimal thickening
30). Therefore, the pathogenesis of chronic allograft ne-
hropathy may be similar to that of cardiac allograft
asculopathy, with both conditions being secondary to
mmune-mediated inflammatory processes. Further study of
he association between AGT and graft vasculopathy is
arranted.
The results from the replication cohort support the results
rom the original cohort by showing an increased likelihood
f graft dysfunction with a greater number of higher-risk
AAS genotypes. The smaller sample size and the shorter
ollow-up time resulted in bias toward survivors; therefore,
e only evaluated the association of RAAS genotypes with
raft dysfunction and not with mortality or other outcomes.
linical relevance. Our findings suggest that knowledge
f the RAAS genotype can be used to identify patients at
isk for rejection, graft dysfunction, graft vasculopathy,
nd early mortality after transplantation. This knowledge
ay be used in the future to tailor monitoring as well as
reatment based on the genotype. Studies in adults with
eart failure reported that survival can be improved in the
igh-risk ACE DD (deletion/deletion) subset of patients
y using high-dose angiotensin-converting enzyme in-
ibitors compared with standard doses (12). The re-
ponse to angiotensin receptor blockers in hypertension is
lso influenced by the RAAS genotype (31). Whether use
f high-dose RAAS inhibitors in patients with a high-
isk RAAS genotype can improve outcomes after trans-
lantation warrants further investigation. Consideration
hould be given to the use of RAAS inhibitors as a form
f long-term immunosuppression.
There were several limitations in the study. The trans-
lanted heart may likely have a different genotype than the
ecipient, which may independently affect graft function.
onor genotype was not known in our study. Therefore, the
ffect of graft genotype and the potential for interaction
etween the recipient and graft genotypes was not assessed.he sample size did not permit us to investigate the role of
ariations in genes that encode the immune pathway that
ay act synergistically with the RAAS genes or be inherited
ith the RAAS genes in a haplotype model. Furthermore,
he study was not powered to detect an interaction between
AAS genotype and effect of angiotensin-converting en-
yme inhibition. The cohort study design began enrolment
n the last 5 years; therefore, the study population was biased
oward long-term survivors of transplantation.
onclusions
atients with a higher number of high-risk RAAS gene
lleles are more likely to experience adverse outcomes after
ardiac transplantation. Early identification of RAAS geno-
ypes in transplantation recipients may be beneficial for risk
tratification, surveillance, and potentially, tailoring treat-
ent regimens.
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